Recce Pharmaceuticals (ASX:RCE) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Change In Receivables?

Recce Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Recce Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Recce Pharmaceuticals's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Recce Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

Recce Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was A$0.15 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Recce Pharmaceuticals's liquidation value for the six months ended in Dec. 2023 was A$-0.82 Mil.

Recce Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Recce Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Change In Receivables Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

Recce Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Recce Pharmaceuticals (ASX:RCE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Recce Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.153	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Recce Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Recce Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.009	-	4.939	+	0.75 * 0.153	+	0.5 * 0
=	-0.82

Recce Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals (ASX:RCE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines